SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, driven by stronger demand for Amtagvi and Proleukin, has fueled a sharp rally and renewed confidence in its commercial trajectory. Traders are debating whether the move reflects a fundamental re-rating or short covering, while pointing to upcoming lung-cancer data as a potential catalyst.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

A newly adopted change-of-control severance policy for AST SpaceMobile executives has fueled buyout and strategic-partner speculation, though traders note the filing is not evidence of an imminent deal. The conversation is split between bullish deal hopes and skepticism, with many also focused on the lack of a confirmed shipment or launch date for BlueBirds 1416.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is rebounding as concerns ease over Oracles Project Jupiter: traders point to assurances that Oracle remains committed to its fuel-cell contract despite the force majeure notice to the project developer. The community is broadly bullish on AI data-center power demand, while some warn that project timing, valuation and sharp price swings remain risks.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares plunged after the FHFA moved to place VantageScore alongside FICO on a unified mortgage pricing grid, raising concerns that lenders could shift from FICOs established scoring model to a cheaper competitor. Traders are debating whether the change materially erodes FICOs mortgage-market advantage or whether the selloff overstates the threat, with some buying the dip and others warning of further pressure.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving attention, though Xeris says it is not for sale and no deal has been confirmed. Traders are debating whether the report could lead to a bid or broader buyer interest, while some caution that the stocks reaction may fade without a concrete offer.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is under pressure as traders debate whether Kalshi and Polymarkets prediction markets threaten sportsbook market share and whether DraftKings investment in its own DKeX platform will weigh on margins. Bulls point to rising DKeX volume and sportsbook activity, while skeptics argue growth may not translate into profits amid heavy spending and competition.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop next-generation 10 kV silicon-carbide technology is drawing attention as a validation of its capabilities and potential defense-market opportunity. Traders are split between viewing the award as a bullish milestone and arguing that its financial value is unclear because it is a prototype program with no disclosed terms, while sharp price swings have fueled sell-the-news and manipulation claims.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Persistent Russell 2000 weakness is the main focus, with traders attributing small caps underperformance versus large-cap tech to rising Treasury yields and expectations for further rate hikes, which weigh on more rate-sensitive companies. Sentiment is mostly bearish and frustrated, though some traders see oversold conditions and are looking for a potential rebound if yields ease.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Auvelitys launch for agitation associated with Alzheimers disease is drawing attention, with traders citing rising prescriptions and analyst commentary as signs of growing uptake. The debate centers on whether that early momentum will translate into sustained sales growth, as some remain cautious about uneven weekly prescription data and AXSMs share-price weakness.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvaris positive Phase 3 results for its oral HAE-prevention drug are driving concern that it could compete with BioCrysts Orladeyo and pressure future market share. Traders disagree on the impact: some fear the competitive threat, while others point to the time before a potential launch, Orladeyos established patient base, and BioCrysts navenibart pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
